Free Trial

Enliven Therapeutics (ELVN) Competitors

Enliven Therapeutics logo
$16.77 -0.16 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$16.77 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELVN vs. PTCT, SRPT, RNA, SWTX, RARE, AKRO, ACLX, ZLAB, CRNX, and VKTX

Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Arcellx (ACLX), Zai Lab (ZLAB), Crinetics Pharmaceuticals (CRNX), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.

Enliven Therapeutics vs.

Enliven Therapeutics (NASDAQ:ELVN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.

Enliven Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -29.46% -27.33%
PTC Therapeutics -50.32%N/A -16.44%

PTC Therapeutics received 564 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 92.86% of users gave Enliven Therapeutics an outperform vote while only 62.11% of users gave PTC Therapeutics an outperform vote.

CompanyUnderperformOutperform
Enliven TherapeuticsOutperform Votes
13
92.86%
Underperform Votes
1
7.14%
PTC TherapeuticsOutperform Votes
577
62.11%
Underperform Votes
352
37.89%

In the previous week, Enliven Therapeutics had 7 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for Enliven Therapeutics and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.78 beat Enliven Therapeutics' score of 0.40 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
8 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
PTC Therapeutics
10 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.1% of Enliven Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Enliven Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$71.58M-$1.92-8.73
PTC Therapeutics$1.77B2.04-$626.60M$6.516.99

Enliven Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Enliven Therapeutics currently has a consensus price target of $37.25, indicating a potential upside of 122.12%. PTC Therapeutics has a consensus price target of $63.25, indicating a potential upside of 38.95%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Enliven Therapeutics is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
PTC Therapeutics
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.64

Summary

Enliven Therapeutics beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELVN vs. The Competition

MetricEnliven TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$822.89M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-8.839.0626.7119.71
Price / SalesN/A251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book2.816.456.774.50
Net Income-$71.58M$143.98M$3.23B$248.22M
7 Day Performance-5.89%2.41%1.80%0.56%
1 Month Performance-6.68%4.56%11.10%13.17%
1 Year Performance-26.74%-2.67%17.11%7.30%

Enliven Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELVN
Enliven Therapeutics
2.4834 of 5 stars
$16.77
-0.9%
$37.25
+122.1%
-26.1%$822.89MN/A-8.8350News Coverage
Analyst Revision
PTCT
PTC Therapeutics
4.1848 of 5 stars
$46.01
+4.0%
$61.92
+34.6%
+18.9%$3.65B$1.77B-7.751,410Gap Up
SRPT
Sarepta Therapeutics
4.8153 of 5 stars
$36.37
+0.3%
$131.22
+260.8%
-69.0%$3.57B$2.23B29.10840Positive News
Analyst Forecast
High Trading Volume
RNA
Avidity Biosciences
1.9199 of 5 stars
$29.33
+5.2%
$66.38
+126.3%
+3.8%$3.53B$10.90M-10.18190Options Volume
SWTX
SpringWorks Therapeutics
2.3665 of 5 stars
$46.12
-0.3%
$52.57
+14.0%
+7.5%$3.46B$191.59M-13.25230High Trading Volume
RARE
Ultragenyx Pharmaceutical
3.9707 of 5 stars
$36.09
+2.8%
$90.93
+152.0%
-12.7%$3.32B$590.69M-5.691,310Positive News
AKRO
Akero Therapeutics
3.8137 of 5 stars
$41.53
+4.2%
$76.29
+83.7%
+138.9%$3.31BN/A-11.0730Insider Trade
High Trading Volume
ACLX
Arcellx
1.6399 of 5 stars
$59.50
+3.4%
$109.31
+83.7%
+23.0%$3.28B$76.81M-83.8080
ZLAB
Zai Lab
2.6281 of 5 stars
$29.40
+0.5%
$47.37
+61.1%
+62.9%$3.24B$418.33M-10.611,950
CRNX
Crinetics Pharmaceuticals
3.5526 of 5 stars
$33.32
+8.6%
$73.00
+119.1%
-39.5%$3.12B$1.04M-8.93210Gap Up
VKTX
Viking Therapeutics
4.4222 of 5 stars
$28.30
+2.7%
$87.15
+208.0%
-57.6%$3.09BN/A-28.3020Positive News

Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners